President Trump endorsed cannabis rescheduling in September of 2024. He said that, if re-elected, his administration would "focus on research to unlock the medical uses of marijuana to a Schedule 3 drug." In August 2025, President Trump confirmed that his administration is actively reviewing the issue.
As the Trump Administration actively reviews the status of cannabis, the Coalition for Cannabis Scheduling Reform (CCSR) is engaging with stakeholders to provide critical information and analysis concerning the urgent need for scheduling reform.
Rescheduling cannabis to Schedule III would mark historic progress toward ending federal prohibition and present a wide range of advantages over the status quo, including:
Reducing the scope of potential criminal liability for cannabis-related activity.
Encouraging prosecutors and sentencing judges to view cannabis as a lower priority when making charging and sentencing decisions.
Providing federal tax relief from tax penalties associated with the enforcement of Section 280E of the Internal Revenue Code, which are particularly burdensome for social equity and small operators.
President Trump endorsed cannabis rescheduling in September of 2024. During the previous administration, six governors, 12 state attorneys general, and the then-Senate Majority Leader all called on the president to proceed with rescheduling.
Scheduling reform enjoys additional support from a growing list of national organizations representing diverse constituencies. A coalition of veterans and patient advocacy organizations urged the previous administration to expedite its administrative review and reschedule cannabis to Schedule III or lower. The American Nurses Association, which represents five million nurses across the U.S., also endorsed rescheduling as “ a positive step toward developing an evidence-based approach for marijuana and related-cannabinoids use in disease and symptom management.”
In June 2023, CCSR released a comprehensive report on the classification of cannabis under the Controlled Substances Act and the urgent need for reform. The report details the advantages of descheduling cannabis or rescheduling it at Schedule III or lower.
In July 2024, CCSR submitted an extensive comment to the Drug Enforcement Administration in support of the Biden Administration's proposal to move cannabis down to Schedule III under the Controlled Substances Act. The document details why cannabis belongs in Schedule III and why treaty issues do not present an obstacle to rescheduling.
We are actively partnering with a broad range of companies, organizations and elected officials in support of cannabis scheduling reform. If you are interested in learning more, please get in touch with us at info@schedulingreform.org.